---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-034987"
form_type: "8-K"
ticker: "SHPH"
cik: "0001757499"
company_name: "Shuttle Pharmaceuticals Holdings, Inc."
filed_at: "2024-09-04T23:59:59+00:00"
generated_at: "2026-05-31T06:28:22.430823+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Shuttle Pharma begins Phase 2 glioblastoma trial; regains Nasdaq compliance

## Summary
- Phase 2 trial of Ropidoxuridine for glioblastoma opened at two sites; four more anticipated this month.
- 40 patients initially randomized to 1,200 mg/day or 960 mg/day; then 14 more on optimal dose.
- FDA Orphan Drug Designation granted for Ropidoxuridine; potential marketing exclusivity.
- Nasdaq non-compliance resolved after filing re-audited financials and delayed Q2 2023 10-Q.
- Trial expected to complete in 18-24 months; primary endpoint survival vs historical controls.

## SEC filing metadata
- accession: 0001493152-24-034987
- form_type: 8-K
- ticker: SHPH
- cik: 0001757499
- company_name: Shuttle Pharmaceuticals Holdings, Inc.
- filed_at: 2024-09-04T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1757499/000149315224034987/0001493152-24-034987-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1757499/000149315224034987/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-034987
- JSON: https://secwatch.observer/filing/0001493152-24-034987.json
- Plain text: https://secwatch.observer/filing/0001493152-24-034987.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.